SEC Form 4 · accession 0001209191-17-066061
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas B Neff
Officer — Chief Executive Officer · Director
Period of report
Dec 14, 2017
Accepted (ET)
Dec 15, 2017 · 7:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 14, 2017 | S | 6,918 | $42.18 | D | 3,060,887 | D | |
| Common StockF1,F3 | Dec 14, 2017 | S | 11,782 | $43.01 | D | 3,049,105 | D | |
| Common StockF1 | Dec 14, 2017 | S | 200 | $43.60 | D | 3,048,905 | D | |
| Common StockF1,F4 | Dec 14, 2017 | S | 360 | $42.09 | D | 128,826 | I | By Family Partnership |
| Common StockF1,F5 | Dec 14, 2017 | S | 58 | $43.08 | D | 128,768 | I | By Family Partnership |
| Common StockF1,F6 | Dec 15, 2017 | S | 10,552 | $41.37 | D | 3,038,353 | D | |
| Common StockF1,F7 | Dec 15, 2017 | S | 8,048 | $42.07 | D | 3,030,305 | D | |
| Common StockF1,F8 | Dec 15, 2017 | S | 300 | $42.78 | D | 3,030,005 | D | |
| Common StockF1,F9 | Dec 15, 2017 | S | 418 | $41.49 | D | 128,350 | I | By Family Partnership |
| Common Stock | holding | — | — | — | 20,000 | I | By Spouse | |
| Common StockF10 | holding | — | — | — | 60,946 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F10The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
- F2The shares were sold at prices ranging from $41.60 to $42.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold at prices ranging from $42.60 to $43.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4The shares were sold at prices ranging from $41.90 to $42.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5The shares were sold at prices ranging from $42.95 to $43.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F6The shares were sold at prices ranging from $40.75 to $41.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F7The shares were sold at prices ranging from $41.725 to $42.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F8The shares were sold at prices ranging from $42.75 to $42.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F9The shares were sold at prices ranging from $41.20 to $41.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.